within Pharmacolibrary.Drugs.ATC.J;

model J01XD02
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.958,
    Cl             = 6e-05,
    adminDuration  = 600,
    adminMass      = 2000 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.05,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0019,
    Tlag           = 10.200000000000001
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>J01XD02</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Tinidazole is a synthetic antiprotozoal and antimicrobial agent from the nitroimidazole class. It is effective against protozoa such as Giardia lamblia, Entamoeba histolytica, and Trichomonas vaginalis, and also used for the treatment of anaerobic bacterial infections. Tinidazole is approved and is in clinical use today for infections caused by susceptible anaerobic organisms and protozoa.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetics in healthy adult volunteers after a single 2g oral dose.</p><h4>References</h4><ol><li><p>Mergenhagen, KA, et al., &amp; Russo, TA (2020). Fact versus Fiction: a Review of the Evidence behind Alcohol and Antibiotic Interactions. <i>Antimicrobial agents and chemotherapy</i> 64(3) –. DOI:<a href=\"https://doi.org/10.1128/AAC.02167-19\">10.1128/AAC.02167-19</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/31871085/\">https://pubmed.ncbi.nlm.nih.gov/31871085</a></p></li><li><p>Lamp, KC, et al., &amp; Lacy, MK (1999). Pharmacokinetics and pharmacodynamics of the nitroimidazole antimicrobials. <i>Clinical pharmacokinetics</i> 36(5) 353–373. DOI:<a href=\"https://doi.org/10.2165/00003088-199936050-00004\">10.2165/00003088-199936050-00004</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/10384859/\">https://pubmed.ncbi.nlm.nih.gov/10384859</a></p></li><li><p>Wood, BA, &amp; Monro, AM (1975). Pharmacokinetics of tinidazole and metronidazole in women after single large oral doses. <i>The British journal of venereal diseases</i> 51(1) 51–53. DOI:<a href=\"https://doi.org/10.1136/sti.51.1.51\">10.1136/sti.51.1.51</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/1092424/\">https://pubmed.ncbi.nlm.nih.gov/1092424</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end J01XD02;
